Sepsis Treatment
Market: Introduction
According to the report,
the global
Increase
in Geriatric Population to Drive Market
The geriatric population
is highly susceptible to chronic diseases and has weak immune systems. The
geriatric population is prone to developing sepsis and is expected to increase
the patient pool across the world, which, in turn, is projected to drive the
global sepsis treatment market during the forecast period. According to United
Nations University (UNU) estimates, the percentage of the world population
above 65 years of age is anticipated to increase from 9% in 2010 to 16% by 2050.
Increase in the population above 65 years of age asserts the
need of safe and effective therapeutics for sepsis treatment. Therefore, rise
in population of this group is a major driver of the market.
Request for
Analysis of COVID19 Impact on Sepsis Treatment Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=81989
Rise
in Novel Pipeline Drugs to Drive Global Market
There is a large patient
population with unmet medical needs and the number is increasing across the
globe. Leading pharmaceutical companies focus on addressing these unmet medical
needs through new product development. A number of drugs for the treatment of
sepsis is under different phases of clinical trial. Leading companies have made
significant investments in clinical R&D, and have also established
strategic partnerships and collaborations to accelerate new product
development. Asahi Kasei Corporation’s ART-123 is currently in phase III
clinical trial and is expected to launch in the first half of 2021.
Sepsis
Treatment Market: Prominent Regions
In terms of region, the
global sepsis treatment market has been segmented into North America, Europe,
Asia Pacific, Latin America, and Middle East & Africa. North America dominated
the global sepsis treatment market in 2020, followed by Europe and Asia
Pacific. According to research, increase in geriatric population leads to rise
in prevalence of atrial fibrillation and other cardiac diseases. This can be
attributed to North America’s dominance of the global sepsis treatment market.
The sepsis treatment market in Europe is anticipated to expand at a
considerable CAGR from 2021 to 2031. The growth of
the market in the region can be ascribed to rise in cases of sepsis, favorable
government rules & regulations, and increase in investment in the R&D
sector for the development of the biopharmaceutical industry.
According to the European
Sepsis Alliance, over 3.4 million people experience sepsis in
Europe per year; 700,000 of them do not survive, and one-third
of the survivors succumb to it within a year. A number of patients face
lifelong repercussions, such as additional physical, emotional, and cognitive
difficulties.
Buy now
Sepsis Treatment Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=81989<ype=S
Product
Launch and Innovation by Key Players to Drive Global Market
The global sepsis
treatment market is consolidated in terms of number of players. The market is
dominated by key players with innovative product offerings, robust and strong
geographic presence, and adoption of technological advancements in the market.
Key players include Baxter International, Inc., Fresenius Medical Care AG &
Co. KGaA, Nipro Corporation, Asahi Kasei, B. Braun Group, CytoSorbents
Corporation, Medtronic plc, Nikkiso Co., Ltd., Medica SPA, Toray Industries,
and Merck & Co., Inc.
In September 2017,
Baxter completed the commercial launch of a new indication for the company’s
oXiris set, which can presently be used to help eliminate extreme levels of
cytokines, endotoxin, and other inflammatory mediators from a patient’s blood.
More
Trending Reports by Transparency Market Research:
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
